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Abstract: Development requires the careful orchestration of several biological events in order to create
any structure and, eventually, to build an entire organism. On the other hand, the fate transformation
of terminally differentiated cells is a consequence of erroneous development, and ultimately leads to
cancer. In this review, we elaborate how development and cancer share several biological processes,
including molecular controls. Transcription factors (TF) are at the helm of both these processes, among
many others, and are evolutionarily conserved, ranging from yeast to humans. Here, we discuss
four families of TFs that play a pivotal role and have been studied extensively in both embryonic
development and cancer—high mobility group box (HMG), GATA, paired box (PAX) and basic
helix-loop-helix (bHLH) in the context of their role in development, cancer, and their conservation
across several species. Finally, we review TFs as possible therapeutic targets for cancer and reflect
on the importance of natural resistance against cancer in certain organisms, yielding knowledge
regarding TF function and cancer biology.
Keywords: transcription factors; embryonic development; evolution; cancer; clinical trials; high
mobility group box (HMG); basic helix loop helix (bHLH); paired box (Pax); GATA
1. Introduction
1.1. Embryonic Development and Cancer: Two Sides of the Same Coin
Embryonic development involves a mass of cells achieving specific cell identities depending
on morphogen gradients and the activation of transcription factors (TFs). These genetic changes
propel ‘stem cells’ to form terminally differentiated cell types. In cancer, a terminally differentiated cell
undergoes dedifferentiation to a stem cell, following which it assumes a new differentiated identity [1].
Interestingly, the cellular and molecular mechanisms are also quite conserved since tumorigenesis is
caused by the reactivation of repressed genes [1]. If development is orderliness and regulation, cancer
is deregulation. While in cancer, the accumulation of mutations in the genome leads to uncontrolled
proliferation and the misdirected establishment of cell identity, embryonic development involves
stem cell proliferation, fate specification, and migration must be streamlined in order to ‘assemble’ an
organism. Studying embryonic tumors provides a case study as to how embryonic development can
progress to cancer. Some examples include retinoblastoma (Rb), neuroblastoma, and nephroblastoma.
An error in stem cell differentiation leads to each of these cancers. RB1, a tumor suppressor and
well-known cell cycle regulator, has mutations in Rb [2]. However, a significant number of carcinomas
are difficult to study since they are embedded amid a large population of differentiated cells [3].
Interestingly, a number of regulators of gene expression are also used as markers for cancer
detection. Octamer binding transcription factor 4 (Oct4) is expressed in pluripotent stem cells and
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is necessary for controlling their pluripotency and self-renewal from gastrulation [4]. Intriguingly,
it is also an established marker of tumor initiating cells (TIC) and embryonic carcinoma cells [5–9].
Oct4 plays an important role in the initiation and progression of cancer. The overexpression of
Oct4, along with Sox2 and Nanog, has been shown to cause the dedifferentiation of glioblastoma
multiforme cell lines into induced glioma stem cells [10,11]. In addition, OCT4 overexpression in
human metastatic melanomas causes a loss of melanoma markers and increases cell migration [12,13].
RNAi mediated knockdown of Oct4 leads to reduced TIC phenotypes [13]. In lung adenocarcinoma,
Oct4 along with Nanog knockdown reversed the epithelial-to-mesenchymal transition (EMT) and
inhibited tumorigenesis and metastasis [14].
Similarly, Myc is also known as a tumor initiation and maintenance factor. In vitro, Myc knockdown
in cancer cell lines decreased cell proliferation and, in some cases, induced apoptosis [15–17]. Myc
overexpression in an embryonic liver leads to proliferation, whereas in an adult liver, it leads to
polyploidy and cell growth [18]. These results have been reported in a large number of tumors
including epithelial tumors (hepatocellular, breast, squamous carcinoma), hematopoietic tumors (T-
and B-cell lymphoma and leukemia) and mesenchymal tumors (osteogenic sarcoma) [19–22] (Figure 1).
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Figure 1. Development and Cancer: Two sides of the same coin. Schematic representation of parallel 
processes in development and cancer. Three examples of these processes have been outlined: i) EMT, 
ii) progenitor proliferation and, iii) cell migration. In the context of development, EMT is involved in 
neural crest development; progenitor proliferation is associated with stem cell maturation and 
commitment while fertilization; zygote formation and migration of the blastocyst to the uterine wall 
involves cell migration. In the context of cancer, EMT is involved in metastasis, progenitor 
proliferation, increased self-renewal and immune evasion while cell migration occurs when cancer 
cells migrate from organs/ blood vessels to the surrounding tissues. Examples of key transcription 
factors that orchestrate physiological processes in both embryonic development and cancer are 
included alongside. 
1.3. Cell Migration: Essential for Development and Cancer Progression  
Placental or blastocyst cells invading the uterine endometrium and cancer cells invading the 
juxtaposed epithelial or endothelial cells use similar cellular mechanisms. It is a multistep process 
including apposition, adherence or attachment, and eventually differentiation following invasion. 
Angiogenesis is a key process established after invasion and inflammation that ultimately provides 
nutrition to invading cells [39,40]. As expected, non-classical HLA class I antigens are recruited for 
both embryonic development and cancer leading to the recognition of both these tissues as self 
[39,41]. In tumors, and during the second trimester of pregnancy, a TH-2 type anti-inflammatory 
immune response is initiated in order to fuel tumor growth and provide sustenance for pregnancy, 
respectively [42,43]. FoxP3, a TF necessary and sufficient for suppressing the immune functions in 
regulatory T-cells [44], is also known to regulate the differentiation of uterine T-cells into regulatory 
T-cells [45–49]. Infertility is a consequence of the absence, or reduced expression of FoxP3 [50]. 
Incidentally, FoxP3 also happens to be a tumor suppressor gene in breast and prostate cancers [51,52]. 
The misexpression of FoxP3, owing to its location on the X-chromosome can lead to carcinogenesis 
[52]. Morphogens, TFs, epigenetic factors, and their downstream signaling cascades interact within a 
cell. We will mention how each of these contribute individually to development and cancer 
progression in the next section.  
A wide range of morphogens such as Wnt, Hedgehog (HH), BMPs, and FGFs are essential for 
the patterning and development of a range of structures including limbs, the heart, and central 
nervous system. A reactivation of these pathways has been observed in tumorigenesis and metastasis. 
For example, the Wnt pathway is necessary for patterning, fate specification and progenitor 
maintenance [53]. Mutations in the tumor suppressor gene, adenomatous polyposis coli, can lead to 
colorectal cancer [54]. Ovarian cancers and hepatoblastoma also show -catenin overexpression, 
Figure 1. Development and Cancer: Two sides of the same coin. Schematic representation of parallel
processes in development and cancer. Three examples of these processes have been outlined: i) EMT,
ii) progenitor proliferation and, iii) cell migration. In the context of development, EMT is involved
in neural crest development; progenitor proliferation is associated with stem cell maturation and
commitment while fertilization; zygote formation and migration of the blastocyst to the uterine wall
involves cell migration. In the context of cancer, EMT is involved in metastasis, progenitor proliferation,
increased self-renewal and immune evasion while cell migration occurs when cancer cells migrate from
organs/ blood vessels to the surrounding tissues. Examples of key transcription factors that orchestrate
physiological processes in both embryonic development and cancer are included alongside.
1.2. Epithelial-to-Mesenchymal Transition: in Development and Cancer
Epithelial-to-Mesenchymal Transition (EMT) refers to the fate transformation of a cell from a stable,
stationary epithelial cell t a more migratory mesenchymal cell that is resistant to apoptosis [23,24]. This
process is as im rtant in implantation, organ development, an embryo f rmati n as i neoplastic
transformation [25]. Placental form tion, the initiation f the primitive streak, and gas rulati n leading
to the separati n of three germinal layers all involve EMT [26]. Wnt-signaling is particularly imp rtant
for EMT during these processes—Wnt3 for EMT during gastrulation and Wnt8c for the formation of
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the primitive streak [27]. Wnt molecules interact with other pathways such as TGF- and FGF receptors
in order to regulate EMT during such developmental processes. The development of one of the best
studied migratory cells in the embryo, neural crest cells, also requires EMT from the neuroectoderm [28].
These cells travel to different parts of the embryo and contribute to facial musculature and melanocytes
for skin pigmentation, among others. Along with signaling through Wnt, Bone Morphogenetic Proteins
(BMPs), Fibroblast Growth Factor (FGF), and c-Myb pathways, neural crest cells need to downregulate
E-cadherin and N-cadherin expression for migration [29–34].
Multiple cancers are marked by the overproliferation of epithelial cells and angiogenesis followed
by invasion through the basement membrane [35]. Malignancy is the final stage of cancer cell migration
to distant sites. EMT has been shown to be a critical mechanism for the spread of epithelial malignancies.
The expression of mesenchymal markers, as is the case with neural crest cells, is a hallmark of EMT
in cancer [35]. A spectrum of signaling mechanisms involved in development are implicated in
carcinomas. TFs such as Snail, Slug, Twist, and FoxD3 are essential for EMT both in development
and cancer progression. Wnt, bone morphogenetic proteins (BMPs), and fibroblast growth factor
(FGF) signaling, along with the loss of E-cadherin by epithelial cells, makes physiological processes in
embryogenesis and carcinoma metastasis nearly identical [36,37] (Figure 1).
While during embryogenesis, the remodeling and diversification of tissues proceeds to generate a
fully functional organism, mutations in the DNA facilitate EMT in cancer and lead to invasion and
metastasis [38].
1.3. Cell Migration: Essential for Development and Cancer Progression
Placental or blastocyst cells invading the uterine endometrium and cancer cells invading the
juxtaposed epithelial or endothelial cells use similar cellular mechanisms. It is a multistep process
including apposition, adherence or attachment, and eventually differentiation following invasion.
Angiogenesis is a key process established after invasion and inflammation that ultimately provides
nutrition to invading cells [39,40]. As expected, non-classical HLA class I antigens are recruited for both
embryonic development and cancer leading to the recognition of both these tissues as self [39,41]. In
tumors, and during the second trimester of pregnancy, a TH-2 type anti-inflammatory immune response
is initiated in order to fuel tumor growth and provide sustenance for pregnancy, respectively [42,43].
FoxP3, a TF necessary and sufficient for suppressing the immune functions in regulatory T-cells [44], is
also known to regulate the differentiation of uterine T-cells into regulatory T-cells [45–49]. Infertility is
a consequence of the absence, or reduced expression of FoxP3 [50]. Incidentally, FoxP3 also happens to
be a tumor suppressor gene in breast and prostate cancers [51,52]. The misexpression of FoxP3, owing
to its location on the X-chromosome can lead to carcinogenesis [52]. Morphogens, TFs, epigenetic
factors, and their downstream signaling cascades interact within a cell. We will mention how each of
these contribute individually to development and cancer progression in the next section.
A wide range of morphogens such as Wnt, Hedgehog (HH), BMPs, and FGFs are essential for the
patterning and development of a range of structures including limbs, the heart, and central nervous
system. A reactivation of these pathways has been observed in tumorigenesis and metastasis. For
example, the Wnt pathway is necessary for patterning, fate specification and progenitor maintenance [53].
Mutations in the tumor suppressor gene, adenomatous polyposis coli, can lead to colorectal cancer [54].
Ovarian cancers and hepatoblastoma also show -catenin overexpression, which is downstream of Wnt
signaling [55,56]. Downstream players at the time of attachment include cell adhesion molecules such as
integrins, immunoglobulin-CAMs, selectins, and cadherins. E-cadherins are important for both mammary
gland development as well as mammary tumors [57,58].
Epigenetic changes are not just markers of embryonic development and cancer, they also play a
major role in both hematopoiesis and the progression of hematological cancer. DNA methyltransferases
are particularly high in embryos [59] and tumors [60,61]. Ten eleven translocation (TET) enzymes are
multi-domain enzymes, important for regulating DNA methylation [62]. They are highly expressed
in blastocysts at the time of attachment and invasion, and are essential for the survival of an
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organism [63,64]. TET enzymes are essential for DNA repair and chromosomal translocations in
normal physiological conditions and therefore prevent carcinogenesis. Mutations in these enzymes
have been implicated in myeloid leukemia [65] and late onset B-cell lymphoma [66,67]. TET2 was
identified as a tumor suppressor and mutations across the gene have been implicated in acute myeloid
leukemia (AML), myeloproliferative neoplasms (MPN), and myelodysplastic syndrome (MDS) [68].
TFs are at the heart of influencing any cancer initiation and progression. The LIM-homeodomain
TFs, reversion-induced Lim (RIL) or PDZ and LIM domain 4 (PDLIM4), promote apoptosis in cancer
cells and, hence, are silenced epigenetically in AML and MDS [69], as well as breast cancer [70]. Earlier
reviews have drawn comparisons between development and cancer with a focus on individual TF
families such as GATA or Pax in the context of specific organs [71]. In this review, we introduce four of
the many TF families that are essential for the regulation of different aspects of embryonic development
as well as cancer; basic Helix-loop-Helix (bHLH), GATA, High Mobility Group box (HMG) and Paired
box (Pax) TFs (Table 1). We have chosen these families since they have been extensively studied in
both development and disease. Parallels between the role of TFs in development and cancer across
multiple TF families, and spanning different organ systems, reveal a broad biological phenomenon,
and therefore fundamental to understanding and eventually targeting cancer. We discuss the domain
structure of the TFs and their role as regulators of development and cancer. We also highlight their role
in development across different species to emphasize their evolutionary conservation. Transcriptional
regulation is essential for almost every process in the existence of an organism. We will therefore
discuss the role of this regulation in the prevention of cancer progression and conclude our review
by discussing some of these molecules as candidates for therapeutics and lessons we can learn from
species that are cancer resistant (Figure 1).
2. High Mobility Group Box (HMG)
The HMG-box domain was originally identified as a duplicated 80-amino acid L-shaped domain
which binds the DNA minor groove and nucleosomes and, thereby, can induce structural changes in
the chromatin fiber [72,73]. HMGs are the most abundant non-histone ubiquitous chromatin proteins
in a cell and can be divided into three structurally distinct classes, namely HMG-nucleosome binding
family (HMGN), HMG-AT-hook family (HMGA), and HMG-box family (HMGB) [72,74–77] (Table 1).
2.1. HMG Proteins: A Superfamily of Chromatin Remodelers
HMGN proteins are characterized by a bipartite nuclear localization signal (NLS), a
nucleosome-binding domain (NBD) and an acidic C-terminal [78]. HMGN proteins bind specifically
to nucleosome core particles to alter and regulate chromatin structure and function [78]. HMGA
proteins contain three copies of a conserved DNA-binding peptide motif called the ‘AT-hook’ and
an acidic C-terminal tail [79,80]. The AT-hook motif is positively charged and preferentially binds to
the AT-rich sequence in the minor groove of DNA [81]. By binding the DNA, HMGA proteins can
induce structural and/or conformational changes in the DNA, as well as promote the recruitment
of additional components, most of which are TFs [82]. HMGB proteins are the most abundant in
the family, with each mammalian nucleus containing approximately 105 to 106 molecules [83]. They
interact with proteins implicated in a diverse range of DNA-dependent cellular processes, including
DNA replication, recombination, the maintenance of genome integrity, and transposition, among
others [84] (Table 1).
2.2. Role in Development
HMGN proteins are expressed in all embryonic tissues and are linked to differentiation [85,86].
HMGN1−/− mice are subfertile, hypersensitive to various stress conditions, such as exposure to UV
light or ionizing irradiation (IR), and have slight defects in corneal epithelium development and
maintenance [87–89]. HMGA proteins have a role in differentiation and spermatogenesis [90].
HMGA1−/− mice suffer from cardiac hypertrophy, hematological malignancies, and type 2
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diabetes [91,92]. HMGA2−/− mice are pygmies characterized by reduced fat tissue and craniofacial
defects [93,94]. HMGB genes are expressed in both embryonic and adult tissue [95]. HMGB1 and
B2 proteins are important for neural stem cell proliferation, differentiation, and maintenance [96].
HMGB1−/− mice show defects in the activation of the glucocorticoid receptor and die within a day of
birth due to hypoglycemia. HMGB2−/− mice show defects in spermatogenesis and the maintenance
of articular cartilage homeostasis in adults, while HMGB3−/− mice exhibit erythrocythemia [97–102]
(Table 1).
Table 1. The role of transcription factors in embryonic development and cancer.
Transcription
Factor Family Subtype Role in Development Role in Cancer
High Mobility Group
Proteins (HMG)
HMGN1 Corneal epithelium development andmaintenance [87–89]
Regulates transcription of
proto-oncogenes and pro-metastatic
genes like c-fos, BCL3, N-cadherin, JunB
and c-Jun [103]
HMGA1
Regulator of adipogenesis [104], stem cell
state [105] and lymphohematopoietic
differentiation; crucial for normal sperm
production in mouse
Overexpressed in colon, breast and
invasive ovarian carcinomas, pancreatic
and non-small cell lung adenocarcinomas
[106]
HMGA2
Neural crest cells specification in Xenopus
(essential for animal growth) [93]; governs
the exit of embryonic stem cells from
pluripotent ground state; cell proliferation
and distal epithelium differentiation
during embryonic lung development
Overexpressed in pancreatic and
non-small cell lung adenocarcinomas
[106]
HMGB1 Neural stem cell proliferation,differentiation, and maintenance [96]
Overexpressed in pancreatic (PDAC),
gastric, colon, hepatocellular, and
non-small cell lung adenocarcinomas
[107]
GATA
GATA1
Development of erythrocytes,
megakaryocytes, mast cells, and
eosinophils [108,109]
Mutations in GATA1 in Down syndrome
patients associated with DS-AMKL [110]
GATA2 Hematopoiesis [111]
Mediates Kras-driven tumorigenesis in
NSCLC; GATA2 mutated in a subset of
human CML [112–114]
GATA3 T-cell lymphopoiesis, self-renewal, anddifferentiation of long-term HSCs [115]
Tumor suppressor and strong prognostic
marker in breast cancer [116]
GATA4 Cardiac angiogenesis and bilehomoeostasis [117,118]
Downregulated in gastric, lung, ovarian,
colorectal, esophageal, glioblastoma, and
large B-cell lymphoma [114,119,120]
GATA5 Cardiac development [121,122]
Downregulated in gastric, lung, ovarian,
colorectal, esophageal, glioblastoma, and
large B-cell lymphoma [119,123]
GATA6 Hepatic and cardiac development[124,125]
Tumor suppressor in astrocytoma;
overexpressed in colon and pancreatic
cancer [126–128]
PAX
PAX1 Maturation of thymocytes [129] Hypermethylated in cervical cancer [130]
PAX2 Prevention of tubular cells from apoptosispost-injury [131,132]
Overexpressed in ovarian, renal cell, and
bladder carcinomas. Regulates ERBB2
expression in breast cancer [133,134]
PAX3
Early neurogenesis; regulation of sensory
neuron generation from precursor cells.
Maintenance of undifferentiated state of
muscle stem cells [135,136]
PAX3-FKHR fusion protein acts as an
oncogene in alveolar
rhabdomyosarcomas. Overexpressed in
primary melanomas [137–139]
PAX4 Protection of pancreaticβ-cells fromapoptosis [140] Upregulated in human insulinomas [141]
PAX5 B lymphopoiesis [142]
Tumor suppressor in hepatocellular
carcinomas; overexpressed in B-cell
neoplasms; good prognostic marker in
breast cancer [143–145]
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Table 1. Cont.
Transcription
Factor Family Subtype Role in Development Role in Cancer
PAX6
Eye organogenesis and neural stem cell
self-renewal, neuroectoderm cell fate
determination [146]
Oncogenic role in pancreatic
adenocarcinoma and glioblastoma
[147–149]
PAX7 Proliferation and maintenance ofpostnatal and muscle satellite cells [150]
PAX7-FKHR fusion protein acts as an
oncogene in alveolar
rhabdomyosarcomas [137]
PAX8 Thyroglobulin regulation; maintenance ofthyroid progenitor cells [151,152]
Oncogenic role in renal, ovarian, lung,
and thyroid cancers and certain
glioblastoma subtypes [153]
PAX9 Development of permanent teeth [154] Oncogenic role in lung cancer and oralsquamous cell carcinomas [155,156]
bHLH
TWIST 1 Osteogenesis and craniofacialdevelopment [157,158]
Induces EMT; activated during tumor
progression [159–161]
TWIST 2 Osteogenesis and bone proliferation [157] Induces EMT; activated during tumorprogression [159]
MYC
Skeletal development, osteogenesis, stem
and progenitor cell maintenance and
self-renewal, organogenesis [162]
Oncogenic role in various cancer
signaling pathways; tumor maintenance;
copy number variations observed in
pancreatic ductal adenocarcinoma
[163,164]
ATOH1 Differentiation of granule cells of thecerebellum and inner ear hair cells [165]
Tumor suppressor; silenced in most
colorectal cancers; induces differentiation
of gastric cancer stem cells; drives
metastasis of medulloblastoma;
lineage-dependency oncogene in Merkel
cell carcinoma.
NEUROD1
Differentiation of inner ear sensory
neurons, cerebellum, and the
hippocampus [166]
Survival and migration of
neuroendocrine lung carcinomas; cell
motility and tumor formation of
neuroblastoma; in cooperation with Otx2,
controls Group 3 medulloblastoma active
enhancer landscape [167]
NEUROD2
Formation of corpus callosum, essential
for communication between the two
cerebral hemispheres [168]
Tumor suppressor and prognostic
biomarker in Glioblastoma; copy number
gains of NEUROD2 in male breast cancer
(prognostic value) [169]
HAND1
Proliferation, differentiation, and
morphogenesis of embryonic ventricle
cardiomyocytes [170,171]
Downregulated in medulloblastoma;
facilitates proliferation and metastasis in
gastrointestinal stromal tumor; silenced
in over 90% of human primary colorectal
tumors. Methylation of HAND1
associated with poor survival in gastric
cancer; involved in thyroid carcinogenesis
[172]
HAND2
Proliferation, differentiation, and
morphogenesis of embryonic ventricle
cardiomyocytes [170,171]
Tumor suppressor in endometroid
endometrial carcinoma. HAND2
suppression upregulates Fgfs in
endometriosis [173].
OLIG1 Oligodendrocyte differentiation in theneocortex [174]
Aberrant DNA methylation in non-small
cell lung cancer [175]
OLIG2 Oligodendrocyte differentiation in thespinal cord [174] Universally expressed in gliomas [176]
DEC1
Embryonic endochondral bone
development [177]; upregulated in
growth plate cartilage and chondrocytes;
cartilage terminal differentiation; blocks
myogenesis in bovine cells [178]
Critical in cell cycle regulation and cell
death in breast and oral cancer; DEC1
induces EMT in pancreatic cancer [179]
DEC2
Proliferation and differentiation of
chondrocytes;
neuronal differentiation; adipogenesis.
Negative regulator of proliferation and
differentiation of chondrocyte-lineage
committed mesenchymal stem cells [180]
Critical in cell cycle regulation and cell
death in breast and oral cancer [181]
Genes 2019, 10, 794 7 of 35
Table 1. Cont.
Transcription
Factor Family Subtype Role in Development Role in Cancer
HES1
Cell fate determination and epidermal
development [182];
epidermal development [183];
heterogenous ES cell differentiation [184];
proneural gene expression and neuronal
differentiation [185]; brain morphogenesis
[186]; development of the arterial pole of
the heart; thyroid gland development
[187].
Deregulated in several cancers and
positively regulate levels of the tumor
suppressor gene p53 [188]
HEY1 &
HEY2
Embryonic vascular development [189];
maintenance of neural precursor cells;
spatial-temporal pattern of mammalian
auditory hair cell differentiation [190].
HEY1 is involved in
odontogenic/osteogenic differentiation
and cardiac development [191].
Deregulated in several cancers and
positively regulates levels of the tumor
suppressor gene p53 [188]
2.3. Evolutionary Conservation
The HMG boxes of these proteins are well conserved through evolution with homologs in plants,
yeast, flies, worms, mammalian cell lines, and animals [192–194]. Despite the conservation of the
primary sequence among members of this superfamily, several genetic mechanisms have resulted in
structural and functional diversity within members [192–194]. Phylogenetic and sequence analyses
have revealed three possible mechanisms for this divergence, namely (i) gene duplication from an
ancient box, (ii) exon shuﬄing/intragenic duplications to explain why some members of the family
carry several HMG boxes, and (iii) the slow accumulation of mutations in newly duplicated genes [192].
2.4. Role in Cancer
Tumor markers are detectable in body fluids such as blood serum and urine, and are powerful
tools for cancer detection and prognosis. A change in the transcriptional profile of HMGs has been
reported in several cancer types. HMGA1 is overexpressed in colon carcinoma, breast carcinomas,
and invasive ovarian carcinomas, whereas it was not detectable in normal colon, breast, or ovarian
tissue [106]. HMGA1 and HMGA2 are overexpressed in pancreatic adenocarcinomas and non-small cell
lung carcinomas (NSCLC), in both squamous and adenocarcinoma histotypes [106]. HMGN1 regulates
the transcription of proto-oncogenes and pro-metastatic genes like c-fos, BCL3, N-cadherin, JunB and
c-Jun involved in tumor progression, in a way which may suppress the development of cancer [103].
The mRNA and protein expression levels of HMGB1 are increased in the lungs of patients with NSCLC,
pancreatic ductal adenocarcinoma (PDAC), gastric cancer, colorectal cancer, hepatocellular carcinoma
(HCC), and correlate with disease development, tumor progression, invasion, poor prognosis, and
metastasis [107] (Table 1).
3. GATA Transcription Factors
The discovery of the GATA TF family has transformed the field of hematology. GATA1, the
founding member of the GATA family, was initially described as a TF binding to DNA sites within
the regulatory regions of several members of α and β-globin families in chickens. Also known
as Eryf1, GATA1 was subsequently cloned, purified, and characterized as a ‘switch factor’ in
erythroid development [195,196]. This led to the cloning of other members of the GATA family,
GATA2 to GATA6. The GATA family shares two highly conserved C2H2-type zinc-finger motifs
(Cys-X2-C-X17-Cys-X2-Cys (ZNI and ZNII)) that are involved in DNA-binding by recognizing the
GATA element (A/TGATAA/G) [108]. GATA1, along with GATA2 and GATA3 are collectively grouped
as a hematopoietic GATA subfamily, while GATA4, GATA5, and GATA6 are classified as an endodermal
GATA subfamily [110,197] (Table 1).
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3.1. Role in Development
GATA1 functions by promoting the development of erythrocytes, megakaryocytes, mast cells,
and eosinophils [109,198,199]. The loss of GATA1 leads to a substantial increase in GATA2 expression,
indicating that GATA1 not only suppresses GATA2 transcription during erythropoiesis, but is also
partly compensated by GATA2. This phenomenon, also known as the ‘GATA switch’, is facilitated
by the displacement of GATA2 from its enhancer by overexpressing GATA1 [111]. GATA3 plays a
pivotal role in T-cell lymphopoiesis—from the generation of T-cell progenitors to CD4+ specification.
GATA3 has also been shown to regulate the self-renewal and differentiation of long-term hematopoietic
stem cells (HSCs) in the bone marrow [115,200,201]. A deficiency of GATA3 during embryogenesis
drastically reduces HSC production in the aorta-gonads-mesonephros region [202].
GATA4, 5, and 6 are highly expressed in the mesoderm and endoderm-derived tissues such
as the stomach, liver, heart, lung, and gonads. GATA4 induces angiogenic factors such as vascular
endothelial growth factor (VEGF) to regulate cardiac angiogenesis by promoting compensation after
injury [117]. Cyclin D2 and GATA4 have been shown to interact and form a positive feedback loop
that enhances the cardiogenic activity of GATA4 [203]. Furthermore, GATA4 promotes bile absorption
in the proximal ileum to restore bile homoeostasis [118]. In the developing heart, GATA5 is expressed
in both the myocardium and endocardium of mouse embryos. The deletion of both the isoforms of
GATA5 has been shown to result in hypoplastic hearts and partially penetrant bicuspid valve [121,122].
GATA6 has been demonstrated to play a role in the proper patterning of the aortic arch arteries, liver
bud growth, and commitment of the endoderm to a hepatic cell fate [124,204]. GATA6, along with its
target gene, Wnt2, forms a forward transcriptional loop to control posterior cardiac development [125]
(Table 1).
3.2. Evolutionary Conservation
GATA transcriptional regulators are widely distributed in fungi, plants, and metazoans and their
DNA-binding domain is characterized by the presence of one or more class IV zinc finger motif(s).
Fungal GATA factors have been shown to be involved in diverse functions such as nitrogen control,
siderophore biosynthesis, light-regulated photomorphogenesis, circadian regulation, and mating-type
switching [205]. In vertebrates, the zinc-finger domains are more than 70% conserved among all the six
GATA binding proteins, although lower homology exists among their amino- and carboxy-terminal
sequences [121]. In non-vertebrates such as Drosophila melanogaster and Caenorhabditis elegans, GATA TFs
contain only a single zinc-finger motif that has undergone modular evolution [206]. Since vertebrates
and invertebrates share only one C-terminal zinc finger (ZNII), it is possible that a single tandem
duplication event might have occurred before the fungal and metazoan lineages diverged, resulting in
two zinc finger motifs in vertebrates [207].
Evolutionary analysis reveals that the plant GATA family is much larger, more varied, and
complex. In contrast to one or two-zinc finger motifs in vertebrates and invertebrates, phylogenetic
analysis reveals the presence of four different classes of zinc fingers in plants. For example, Arabidopsis
thaliana and rice (Oryza sativa) genomes contain 29 and 28 loci respectively that encode putative GATA
factors that can be grouped into seven different subfamilies [208]. The GATA subfamily VI in plants
consists of a tri-zinc finger protein, which has not been previously reported in eukaryotes. Plant GATA
factors, unlike animals and fungi, have also been found to be associated with additional domains,
such as CONSTANS, CO-like, and TOC1 (CCT) domain, an acidic domain or a transposase-like
domain, involved in light signaling or nitrate-dependent transcriptional pathways [209]. Although it
is unclear, multiple models of evolution including gene duplication and exon shuﬄing may explain
the underlying basis of the GATA family expansion in plants.
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3.3. Role in Cancer
The loss of expression, overexpression, or mutation of GATA factors have been associated with a
multitude of cancers including leukemia, colorectal, lung, and breast cancers. Acute megakaryoblastic
leukemia (DS-AMKL) seen in Down Syndrome patients is mostly associated with point mutations
within the N-terminal zinc finger motif of GATA1. This results in a truncated form of GATA1
(GATA1s) that lacks N-terminal amino acids [110]. The presence of this mutation inhibits GATA1’s
ability to bind the hematopoietic transcription co-factor FOG1 (friend of GATA) and affects platelet
production [210,211]. Although less is known about the direct role of GATA2 in cancer, a subset of
human chronic myelogenous leukemia (CML) patients harbor two mutations in the zinc finger domain
of GATA2 [112]. Furthermore, GATA2 is required for Kras-driven NSCLC tumorigenesis [212]. Nearly
10% of human breast cancers are associated with GATA3 mutations in the C-terminal zinc finger of ZNII.
The downregulation of GATA3 is a strong prognostic marker, especially in the cases of estrogen receptor
(ER)-negative breast cancers, and is linked with aggressiveness and poor survival [116,213]. GATA3
restoration in breast cancer cell-lines induces miR-29b expression, leading to repressed metastasis and
reduced tumor outgrowth [214,215].
The downregulation of GATA4 and GATA5 expression due to epigenetic silencing, such as CpG
island hypermethylation and histone hypermethylation is often observed in cases of gastric, lung,
ovarian, colorectal, oesophageal cancers, glioblastoma, and diffuse large B-cell lymphoma [119]. GATA6
acts as a double-edged sword in different cancer types. For example, it acts a tumor suppressor in
astrocytoma while it is overexpressed in human colon cancer and pancreatic carcinoma [126,216,217].
Although not much is known about GATA factors, improved insights into GATA regulation at
transcriptional, translational and post-translational levels can be exploited as novel biomarkers in
cancer (Table 1).
4. Pax Transcription Factors
Paired box (Pax) genes encode TFs that orchestrate complex processes such as embryogenesis
and are crucial for maintaining stem-cell pluripotency and stem cell-lineage specificity during
development [218,219]. Pax proteins are characterized by the presence of three conserved elements: two
DNA-binding domains—the paired domain (PD) and homeodomain (HD)—and the short octapeptide
sequence (OP) located between the PD and HD domains [220]. Deletion of the OP motif in some Pax
proteins is indicative of a transcriptional inhibitory activity [221]. PD is composed of 128 amino acids
and makes sequence-specific contacts with DNA. A second paired-type HD domain found in several
Pax members consists of 60 highly conserved amino acid residues. It shares strong homology with
other homeobox gene products. PD can either bind DNA independently or as a cooperative interaction
with HD domain. However, isolated HD domains have not been demonstrated to bind DNA [222,223].
Additionally, a transactivation domain (TD) at the carboxy terminus of Pax is a proline, serine-, and
threonine rich region mediating transcriptional regulation [146,224].
The Pax family is composed of nine TFs (PAX1-PAX9) in humans as well as in mice (Pax1-Pax9).
They are subdivided into subgroups I–IV based on the presence, absence, or truncation of a
homeodomain—subgroup I (PAX1, PAX9), subgroup II (PAX2, PAX5, PAX8), subgroup III (PAX3, PAX7)
and subgroup IV (PAX4, PAX6) [225]. The important roles of Pax genes in development underscore
their functions in adult tissue regeneration and the repercussions of their aberrant loss, overexpression,
or re-expression are associated with pathology (Table 1).
4.1. Role in Development
During development, the temporal and spatial expressions of Pax genes are tightly regulated. Pax
expression is observed during proliferation but is switched off during terminal differentiation [223]. Pax
gene expression in adult tissues has often been associated with tissue homeostasis. A small fraction of
cortical cells in the adult thymus express PAX1, where it promotes the maturation of thymocytes [129].
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PAX2 expression has been documented in medullary regions of the adult kidneys, mammary gland,
transitional urothelium of the ureter and bladder as well in the epithelial lining of fallopian tubes of
females [226–228]. Upon kidney injury, Pax2 expression re-emerges and prevents tubular cells from
apoptosis in the initial stage of regeneration [131,132]. Pax3, expressed during early neurogenesis,
regulates the generation of sensory neurons from precursors that originate from the neural crest [135].
PAX3 is also expressed in muscle stem cells in adults and melanoblasts (melanocyte stem cells) located
in the bulge region of hair follicles, where it maintains their undifferentiated state [136]. Although
not much is known about Pax4 function, its expression was shown to confer a protective function in
pancreatic β-cells, increasing its replicative potential by transcriptionally activating Myc expression. It
also protects β-cells from apoptosis by the activation of the anti-apoptotic Bcl-xL [140].
PAX5 is involved in B lymphopoiesis, specifically in the pathway regulating V- to -DJ
recombination [142]. Intriguingly, re-programming of mature B-cells to pluripotent stem cells
was shown to require Pax5, in addition to Sox2, Oct4, Klf4 and Myc [229]. During development,
Pax6 is expressed in multiple brain regions and pancreatic islets, and is essential for eye
organogenesis [146,230,231]. Pax6 is crucial for neuroectoderm cell fate determination [232].
Furthermore, the delicate balance between neural stem cell self-renewal and neurogenesis is regulated
by Pax6 [233]. It was also reported that Pax6 is re-expressed during corneal wound repair. PAX6
deficiency was correlated with increased stromal cell apoptosis and cell-proliferation [234–236]. On
the other hand, Pax7 maintains the proliferation and survival of postnatal satellite cells [237]. It is also
found in muscle satellite cells, which are needed for tissue repair and regeneration following muscle
injury [150].
In the adult thyroid, Pax8 plays a role in regulation of thyroglobulin (Tg), thyroid peroxidase (Tpo),
and sodium/iodide symporter (NIS) that are essential for thyroid hormone synthesis [151,152,238].
Pax8 is also important for the maintenance of adult thyroid stem/progenitor cells [239]. Additionally,
PAX8 expression has been documented in adult kidneys, specifically in the Bowman’s capsule and
medullary regions, which are sites of renal stem/progenitor cells [152,240,241]. PAX9, like PAX8, is
also expressed in the adult thymus and eosphagus [129]. Furthermore, PAX9 is also important in
development of permanent teeth [154]. Thus, although Pax expression is relatively rare in adult
tissues, this expression may be crucial for the survival of stem cell populations and maintenance of
pluripotency (Table 1).
4.2. Evolutionary Conservation
Pax genes are specific to the animal lineage and have not been found in unicellular organisms,
fungi or plants so far [220]. Four Pax genes (Pax1/9, Pax2/5/8, Pax3/7, and Pax4/6) have been found in the
basal chordates, amphioxus (e.g., Brachiostoma floridae) and tunicates (e.g., Ciona intestinalis) [220,242].
Phylogenetic analyses indicated that, in the ancestral chordate, a single Pax gene of each subfamily
was present, which gave rise to the amphioxus Pax. Subsequently, two major rounds of whole genome
duplications occurred that gave rise to multiple vertebrate Pax subfamily copies [220,242,243]. Another
partial duplication occurred subsequently, resulting in the nine Pax genes in mammals [244,245].
An alternative scenario would be that more Pax genes would have arisen after two whole genome
duplications and were then lost during the vertebrate evolution [246,247].
Overall, purifying the selection appears to be the main factor responsible for the molecular
evolution of the Pax family in chordate species. However, there are some indications of potential
group-specific changes that are beyond this general pattern [248]. Phylogenetic analysis revealed that
Pax2 and Pax5 ancestors were most likely involved in a round of complete vertebrate duplication
while Pax8 was the most recent gene to appear by local gene duplication in this family. Lizards and
birds have lost Pax4 and Pax8 [248]. Accelerated evolutionary rates were suggested for the Pax4, Pax8,
and Pax7 genes. Thus, the asymmetric evolution of the Pax family genes can be associated with the
emergence of adaptive novelties in the chordate evolutionary trajectory [248].
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Moreover, two other alternative scenarios have been proposed to explain the evolution of Pax
genes. One scenario assumes that the first Pax gene comprised of the PD domain alone (represented by
PaxA/neuro) while the second Pax gene appeared as a result of the fusion of PD with an HD-containing
gene [249]. Such capturing events could have happened several times and given rise to diverse primary
Pax types [250]. The other scenario considers only one capturing event followed by gene duplications
giving rise to the distinct Pax forms [249,251,252]. In this model, the PaxA gene is not assumed to
denote the progenitor type, but instead is a remnant form lacking the HD domain.
4.3. Role in Cancer
Pax genes belonging to subgroups II and III that contain OP and a partial HD are involved in cell
motility, cell survival, and self-sufficiency in growth signals, thus favoring tumor progression [253].
Conversely, Pax genes in subgroups I and IV that only contain one of these domains are rarely involved
in cancer, or are indicators of favorable prognosis in cancers [225].
PAX1 was found to be hypermethylated in cervical cancer tissues [130]. On the other hand,
PAX2 is expressed in ovarian cancer, renal-cell carcinomas (RCC) and in some bladder carcinomas,
where it is crucial for tumor survival since PAX2 regulates the surface protein metallopeptidase, A
Disintegrin and metalloproteinase-domain containing protein 10 (ADAM10) [133]. Over 70% of RCC
cell-lines bear deletions/mutations in the Von Hippel Lindau (VHL) tumor suppressor gene that, in
turn, promotes PAX2 expression in renal tumors [254,255]. In breast cancer, PAX2 was reported to form
a complex with the ER and regulate Erythroblastic Oncogene B2 (ERBB2), thus determining the response
to tamoxifen [134]. In addition, resistance to apoptosis in Kaposi’s sarcoma is associated with PAX2
expression [256]. In a majority of alveolar rhabdomyosarcomas (ARMS), PAX3 has been shown to
undergo chromosome rearrangement with FOXO1/FKHR [137,138]. The PAX3-FKHR fusion in ARMS
is a strong transcriptional regulator and is thought to be a dominant-acting oncoprotein [257]. PAX3 is
also expressed in primary melanomas and its expression in sentinel lymph nodes has been considered
as a prognostic marker for aggressive tumors with a poor outcome [139]. PAX4 is upregulated in human
insulinomas [258] and functions as a survival factor in rat insulinoma cells via Bcl-xL upregulation [141].
Most B-cell neoplasms, including B-cell lymphoma demonstrate PAX5 overexpression [143].
However, in HCC, PAX5 acts as a tumor suppressor by interacting with the p53 signaling pathway [144].
In breast cancer, PAX5 expression enhances epithelial behavior and is associated with better prognosis
in patients [145]. In PDAC, Pax6 promotes cancer progression by the activation of the receptor tyrosine
kinase, c-met [147]. Conversely, PAX6 expression was observed to suppress the invasiveness of
glioblastoma cells by regulating the expression of matrix-metalloproteinase 2. In addition, PAX6
also reduced angiogenesis and increased glioma cell susceptibility to detachment and oxidative
stress [148,149,259].
Similar to PAX3, albeit less frequently, PAX7 also undergoes rearrangements with FOXO1/FKHR
in ARMS [137]. PAX8 undergoes rearrangements with peroxisome proliferator-activated receptor
γ (PPARγ) in thyroid adenocarcinomas [260]. PAX8 was also shown to be essential for basal E2F1
transcription and maintaining the stability of its TF c-factor, Rb, in renal, ovarian, and thyroid
cancers [241]. In addition, PAX8 also regulates telomerase in certain glioblastoma cell lines [153].
PAX9 is amplified and has been implicated in promoting the proliferation of lung cancer cells [155].
Oncogene-induced cell-survival in oral squamous cell carcinomas is mediated by PAX9 [156]. Thus,
Pax genes play a major role in conferring growth and survival advantages to cancer cells by regulating
cell plasticity [261] (Table 1).
5. bHLH Transcription Factors
Basic helix loop helix (bHLH) TFs are named on the basis of their structure, and have two
evolutionarily conserved domains, namely the basic domain that binds to the E-box DNA sequences
(CANNTG) to regulate transcription and the helix-loop-helix (HLH) domain, important for protein
homo- or hetero-dimerization. Post dimerization, they bind to the E-box. The dimerization happens
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via two alpha-helices connected by a non-conserved loop region [262]. Class I bHLH molecules are
expressed quite ubiquitously, whereas Class II molecules are tissue specific [263,264]. One such tissue
specific bHLH factor is Twist, which regulates EMT in both development and cancer [159,160,265]. The
bHLH TF superfamily is imperative for proper development, including the fate specification and cell
differentiation of almost all the tissues of any organism from flies to humans [263]. One example of the
same TF playing important roles in development and cancer is Myc. Elevated levels of MYC are seen
in 60%–70% of all cancers [266]. These are also bHLH TFs and play an important role normally in cell
cycle, differentiation, and angiogenesis (Table 1).
5.1. Role in Development
Proneural bHLH TFs were first identified in Drosophila for their ability to confer neural identity to
ectodermal tissue. In contrast, vertebrate bHLH genes act after neural identity has been determined.
The Achete-Schute complex and Atonal are two neural-specific bHLH gene families in vertebrates,
based on their homology in flies, that play a wide range of roles in development [262,267]. Proneural
genes Neurogenin 1, 2, and Ascl1 are required for neural differentiation in both the peripheral and
central nervous systems (CNS) [268–275]. Neurogenin 2 and Ascl1 have in fact been used for neuronal
reprogramming due to their ability to specify cell fates based on their target genes [157,276–280]. Atoh1
of the Atonal family is also important for the differentiation of granule cells of the cerebellum and of
inner ear hair cells [165]. The bHLH family of neural specific genes also include NeuroD1, D2 and D6,
and the Olig family. These are important factors for differentiation to neurons and oligodendrocytes
within the CNS. NeuroD1 is necessary for the differentiation of inner ear sensory neurons, granule cells
of the cerebellum and the hippocampus [166,281]. NeuroD2 and D6 are necessary for the formation of
the corpus callosum, needed to communicate between the two cerebral hemispheres [168]. Olig1, 2
and 3 are necessary and sufficient for oligodendrocyte differentiation in the neocortex, spinal cord and
the cerebellum, respectively [174,282,283].
Besides their extensive role in neural development, bHLH TFs have also been well-studied in
the development of other structures. Math1, Neurogenin 3, and NeuroD1 play a sequential role in
the development of gastrointestinal entero-endocrine cells—specification, segregation to the secretory
lineage and differentiation [284–287]. Hand1 and Hand2 play critical roles in the proliferation,
differentiation, and the morphogenesis of embryonic ventricle cardiomyocytes [170,171,288]. Twist1
and Twist2 play a major role in bone formation or osteogenesis. They are important for osteoprogenitor
proliferation and differentiation via FGF signaling [157]. Twist1 is expressed in the skeletal mesenchyme
and also important for craniofacial development, also via FGF signaling [158,289,290] (Table 1).
5.2. Evolutionary Conservation
bHLH is a large family of TFs that control the developmental and physiological processes of
eukaryotes, and exist in fungi, plants, and animals [267]. Several TFs of this family are evolutionarily
conserved across different species and play a crucial role during development. Orthologs of Nephew
of atonal 3 (Nato 3), a proneural gene, are conserved across Drosophila, C.elegans, mice, and humans.
They are highly similar in their bHLH domain [291]. The Hand gene family is also highly conserved
across Drosophila and mammals, and is essential for heart and vascular development [292].
In yeast, bHLH TFs promote cell cycle control and transcriptional enhancement [293,294]. The
bHLH members are the second largest class of plant TFs and play a pivotal role in plant growth and
maintenance. Phytohormone signaling cascades impinge on to bHLH TFs for Arabidopsis development
and defense [295]. SlPRE2, an atypical bHLH member, controls the pigmentation of tomato fruit and
the morphology of the plant [296].
The bHLH family has expanded in plants and animals following evolutionarily independent
events [267]. It is unclear whether bHLH TFs evolved from a single common ancestor or via domain
shuﬄing from an ancestral protein [297]. Genome segment and tandem duplications are thought
to have led to bHLH gene family expansion in plants [298,299], whereas studies in animals suggest
Genes 2019, 10, 794 13 of 35
single-gene duplication [300]. The field is still debating whether bHLH TFs expanded in parallel with
the evolution of multicellularity, or with the colonization of land [301,302]. Evolutionary analyses
of several land plants, chlorophytes, and red algae suggest that the first plants had minimal bHLH
genes, and that all modern plant bHLH proteins descended and evolved via a large number of gene
duplications [302,303].
5.3. Role in Cancer
An innumerable number of bHLH TFs are important for cellular differentiation, cell cycle arrest,
and apoptosis. Therefore, it isn’t surprising that they play a major role in tumor growth and progression.
Myc is a proto-oncogene that is dysregulated in several types of cancer. Copy number variations
in MYC occur very frequently among other genetic events leading to human cancers, for example,
in PDAC [163]. Myc is downstream of multiple important signaling pathways such as PI3K [304],
Notch [305], Wnt-APC [306], and KRAS-ERK [307] that are implicated in different types of cancers. More
importantly, Myc is responsible for both initiating, as well as maintain the tumor [164,308]. Hes1 and
Hey1 positively regulate p53 levels, a tumor suppressor gene [188]. Both these TFs are dysregulated in
several different cancers [309]. Twist induces EMT and is activated during tumor progression [159–161].
BHLHE40 (DEC1) and DEC2 are important for the regulation of the cell cycle via cyclin D1 and cell
death in oral and breast cancer cells [179,181]. Dec1 also leads to EMT in pancreatic cancer cells [310].
The expression of TCF3 (E2A) is enhanced in prostate cancer, thereby promoting tumor progression—it
provides resistance to apoptosis in prostate cancer [311]. Hypoxia-inducible factor 2 alpha (HIF-2) aids
the progression of neuroblastoma and other cancers in non-hypoxic conditions by recruiting Argonaut
2 [312].
The bHLH TFs have been shown to be downregulated in pancreatic cancer and, in fact, a
high-throughput screen has identified small molecules as bHLH activators, which may be used as
therapeutic targets [313] (Table 1).
6. Discussion
6.1. Transcription Factors—Crucial Proteins for Development and Homeostasis
In this review we have discussed four families of TFs that have been well studied in both,
development and cancer. However, there are a multitude of TFs that have important roles in multiple
physiological processes and derangements. In fact, 294 cancer-related TFs have been listed in different
resources [314,315]. The LIM family of TFs has been exhaustively studied in development [316]
and cancer [317]. A few other TFs that have been studied considerably well include the specificity
proteins (Sp) family [318], forkhead box (FOX) family [319–322], HOX genes [323,324], ETS-domain
TFs [325–327], steroid reproductive hormone receptors [328,329] and zinc finger ZBTB proteins, with
N-terminal BTB/POZ domains [330].
While we have limited our review to a subset of TFs, development and cancer are regulated by
a number of epigenetic factors and noncoding RNA molecules. They have been discussed at length
elsewhere [331]. Recently, these molecules have also been targeted for cancer therapy [314,332].
6.2. Therapeutic Targeting of Transcription Factor: Need of the Hour
TFs regulate a wide range of biological processes and therefore are essential for maintaining
homeostasis. They account for nearly 20% of the identified oncogenes and although promising
candidates for targeting cancer [314,315], they were considered undruggable up until this decade [333].
A better understanding of their mechanisms of action and structural interactions with the cognate
DNA sequence and protein regulators have led to the discovery of useful drug candidates. Despite
this progress, the immense repertoire of downstream targets, threshold of expression in normal versus
cancerous tissue, redundancy, and compensation by other TFs, epigenetic modulation [334], and vastly
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different mutations in the same gene across individuals [335] makes it arduous for TFs to be effectively
targeted [314].
Targeted genome editing technology mediated by CRISPR shows great promise in both
fundamental and clinical research. It has been employed for the increment or attenuation of gene
expression more reliably than any other genetic engineering technology [336,337]. Targeting TFs using
this approach could be a reasonable therapeutic route since they control the fate of a cell, in normal
physiology and in cancer. Catalytically inactive dCas9 can be recruited to specific sites on the DNA,
which is particularly useful when fused to TFs. This would allow the activation or repression of certain
downstream genes [338,339]. Direct targeting of cancer markers such as MYC has been explored to
reduce genetic alterations leading to uncontrolled proliferation and metastasis [340]. CRISPR may
prove useful in such targeting. In addition, the CRISPR system has been tested for light-induced
spatio-temporal control of gene expression [341]. DNA break caused by CRISPR/Cas9 triggers two
mechanisms of DNA repair: non homologous end-joining (NHEJ) and homology-directed repair
(HDR). Of these, HDR is high fidelity and therefore allows precise DNA editing [342,343]. A novel
CRISPR-barcoding tool utilizing HDR enables identification of mutation such as p53 mutation in breast
cancer cells (MCF7) and even correcting a mutation, for example, ALK-F1174L in Kelly neuroblastoma
cells [344].
As discussed above GATA, HMG, PAX, and bHLH have been implicated in cancer and the
characterization of these molecular targets in vitro and in vivo studies have led to the development
of several preclinical and clinical studies. The targeted modulation of these TFs can be used for
the development of new cancer treatment [337,345–348]. We have summarized a list of the ongoing
preclinical and clinical trials studies for various TF targets (Figure 2, Table 2).Genes 2019, 10, x FOR PEER REVIEW 15 of 35 
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namely HMG, GATA, PAX and bHLH in development and cancer. HMGA1 binds DNA through
‘AT-hook’ motifs to induce or stabilize DNA and/or protein conformations. This triggers enhanced
transcription by RNA polymerase II. GATA switch occurs when GATA-1 displaces GATA-2 fro FOG-1
when hematopoietic stem/progenitor cells (HSPC) undergo first steps of erythrocytic/megakaryocytic
differentiation [349]. PAX6 and Sox2 cooperate functionally and regulate lens developme t and eye
morphogenesis [350]. Two ifferent phosphorylation states of Neurogenin 2 (Ngn2), a bHLH TF, leads
to either differentiation or neurogenesis [351]. Examples of candidate drugs targeting ach TF are
highlighted (T bl 2).
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Table 2. Ongoing preclinical and clinical trials on transcription factor targets in different types of cancer.
Molecular Target Candidate Drug Condition or Disease Stage of Testing Other Targets & Disease Conditions Direct or NonselectiveInhibition
Reference/ClinicalTrial.gov
Identifier
HMGB1 Sodium salicylate Lungadenocarcinoma Preclinical
Targets—Mitogen-activated protein
kinases (MAPK), Caspase 3, NF-κb,
p38 kinase, AP-1
Disease—Acute Myeloid Leukemia
Nonselective [352]
HMGB1 Anti-HMGB1 antibody Colorectal cancer Preclinical
Disease—Stroke, Epilepsy,
Neudegenerative diseases,
neuropathic pain
Direct [353]
GATA-3 MLN9708 Lymphoma Phase II
Targets—p38 kinase, Janus Kinase
(JNK), NF-κb
Disease—Breast Cancer
Nonselective NCT02158975
GATA-2
Busulfan, Fludarabine,
Busulfan and
Cyclophosphamide
Myelodysplastic
Syndromes Phase II
Disease—Chronic Myelogenous
Leukemia, Lymphomas Chemo-therapy NCT01861106
Pax3-Foxo1 Thapsigargin AlveolarRhabdomyosarcoma Preclinical
Targets—Sarco/endoplasmic reticulum
Ca2+ ATPase (SERCA), Nicotinic
acetylcholine receptors
Nonselective [354]
bHLH Pitavastatin Pancreatic cancer Preclinical
Targets—3-hydroxy-3-methyl glutaryl
coenzyme A reductase
Disease—Hypercholestrolemia and
dyslipidemia
Nonselective [313]
Reverse the association
between Myc and its obligate
bHLH heterodimerization
partner, Max
10058-F4 Promyelocyticleukemia Preclinical
Targets—MYCN, Myc/Max
dimerization
Disease—MYCN-amplified
neuroblastoma, Acute Myeloid
Leukemia
Direct [355]
Myc Mycro1, Mycro2 andMycro3 Leukemia Preclinical Targets—Myc/Max dimerization Direct [314,356,357]
MYC
Lenalidomide
and Combination
chemotherapy
B-cell lymphoma Phase I/II Targets—CRL4 E3 Ubiquitin ligaseDisease—Multiple Myeloma Nonselective NCT02213913
MYC Ibrutinib GastrooesophagealCancer Phase II
Targets—Bruton’s tyrosine kinase
(BTK), CD20
Disease—B-cell cancers such as
mantle cell lymphoma, chronic
lymphocytic leukemia and
Waldenstrom’s macroglobulinemia
Nonselective NCT02884453
MYC DA-EPOCH-R followed byNivolumab B-cell lymphoma Phase II
Targets (Nivolumab)—PD-L1
Disease—Squamous non-small cell
lung cancer, renal-cell carcinoma,
small cell lung cancer
Nonselective NCT03620578
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6.3. Natural Resistance Against Cancer: Learning from Life
The task of suppressing somatic mutations in larger organisms and those with a longer lifespan is
more challenging. According to Peto’s paradox, there is no correlation between the body size, longevity
and increased risk of developing cancer. Therefore, in evolution, larger animals have mechanisms
to suppress cancer by either eliminating certain proto-oncogenes or duplicating tumor suppressor
genes [358–360]. Elephants appear to have low cancer occurrence rates since they have re-functionalized
the leukemia inhibitory factor pseudogene 6 (LIF6) with pro-apoptotic functions [361]. In addition, the
duplication/multiplication of tumor-suppressor protein TP53 seems to provide another explanation,
even though most are processed pseudogenes [362]. DNA damage leads to TP53 upregulation which,
in turn, transcriptionally upregulates LIF6. A TP53 response element perhaps evolved co-incident with
large body sizes [363]. The analysis of cancer prevention in elephants suggests a lack of understanding
of the full extent of the tumor-suppressive capacity of p53 in humans [364].
Cetacean species, another order of large mammals could also be effective models for studying
cancer [365]. The beluga whales of the St. Lawrence estuary have a high occurrence of cancer,
sometimes even surpassing humans, but are an exception among other cetaceans. In pilot whales,
bottlenose dolphins, and other toothed whales, cancer is a rare event [366]. The bowhead whales
have an extraordinarily long lifespan [367]. Comparative genomics and transcriptomics have revealed
the duplication of proliferating cell nuclear antigen (PCNA) and other genes involved in DNA repair
in these animals [368]. Cross-species comparisons allow us to understand cancer resistance in other
mammals as well—for example, naked mole rats and blind mole rats are remarkably resistant to
cancer [369].
Fundamentally, plants are different from animals owing to their cell walls. Even though
plants develop tumors, the cell wall exerts control on cancer metastasis. Plant tumors are mainly
caused by pathogens such as Agrobacterium (crown gall), geminivirus, and Ustinaginales among other
fungal infections [172,370]. In the absence of infections, they are remarkably resistant to neoplastic
transformation and hence, cancer. However, spontaneous tumors arise in interspecific hybrids of certain
plant species, such as Nicotiana (tobacco) [371]. Most of these tumors are caused by phyto-hormonal
imbalance [372]. Interestingly, homologs of an extensively studied tumor suppressor and cell cycle
regulator, Rb, plays an important role in tumorigenesis in divergent multicellular species [373].
Rb-related (RBR) in plants are implicated in tumor-like growth upon infection with Agrobacterium and
geminiviruses [374]. Although exhaustive research exists on mammalian Rb and its role in cancer
compared to its plant homolog, they have similar roles in cell cycle progression, regulation of TFs via
chromatin modifying proteins and role in cell fate decisions [373]. Comparing the molecular aspects
of tumor-initiation and progression with plants may provide insights into cancer prevention and the
understanding of its biology.
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Acute megakaryoblastic leukemia AMKL
Alveolar rhabdomyosarcomas ARMS
basic Helix-loop-Helix bHLH
Bone Morphogenetic Protein BMP
Central nervous system CNS
Chronic myelogenous leukemia CML
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Cystein-rich Polycomb-like Proteins CPP
Epithelial-to-mesenchymal transition EMT
Fibroblast Growth Factor FGF
Forkhead box FOX
Hedgehog HH
Hepatocellular carcinoma HCC
Hematopoietic stem cells HSCs
Hematopoietic stem/progenitor cells HSPC
High Mobility Group box HMG
HMG-AT-hook family HMGA
HMG-box family HMGB
HMG-nucleosome binding family HMGBN
Homeodomain HD
Homology-directed repair HDR
Leukemia Inhibitory Factor pseudogene 6 LIF6
Myelodysplastic syndrome MDS
Myeloproliferative neoplasms MPN
Nephew of atonal 3 Nato 3
Neurogenin2 Ngn2
Non homologous end-joining NHEJ
Non-small cell lung carcinomas NSCLC
Nuclear localization signal NLS
Nucleosome-binding domain NBD
Octamer binding transcription factor 4 Oct-04
Octopeptide OP
Paired box genes PAX
Paired domain PD
Pancreatic ductal adenocarcinoma PDAC
Proliferating cell nuclear antigen PCNA
Renal-cell carcinomas RCC
Specificity proteins Sp
Retinoblastoma Rb
Ten Eleven Translocation TET
Transactivation domain TD
Tumor initiating cells TIC
Thyroglobulin Ty
Thyroid peroxidase Tpo
Transcription Factors TFs
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